Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000664 |
| _version_ | 1797285046961307648 |
|---|---|
| author | Natali Pflug Geothy Chakupurakal Anna-Maria Fink Sandra Robrecht Marco Herling Paula Cramer Udo Holtick Sebastian Theurich Johannes Schetelig Kirsten Fischer Matthias Ritgen Christof Scheid Barbara Eichhorst Peter Dreger Michael Hallek Michael von Bergwelt-Baildon on behalf of the German CLL Study Group |
| author_facet | Natali Pflug Geothy Chakupurakal Anna-Maria Fink Sandra Robrecht Marco Herling Paula Cramer Udo Holtick Sebastian Theurich Johannes Schetelig Kirsten Fischer Matthias Ritgen Christof Scheid Barbara Eichhorst Peter Dreger Michael Hallek Michael von Bergwelt-Baildon on behalf of the German CLL Study Group |
| author_sort | Natali Pflug |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:57:32Z |
| format | Article |
| id | doaj.art-2bb4b1c0048143b29f0e46696ee44349 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:57:32Z |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-2bb4b1c0048143b29f0e46696ee443492024-03-02T11:42:05ZengWileyHemaSphere2572-92412021-12-01512e66410.1097/HS9.0000000000000664202112000-00002Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted TherapiesNatali Pflug0Geothy Chakupurakal1Anna-Maria Fink2Sandra Robrecht3Marco Herling4Paula Cramer5Udo Holtick6Sebastian Theurich7Johannes Schetelig8Kirsten Fischer9Matthias Ritgen10Christof Scheid11Barbara Eichhorst12Peter Dreger13Michael Hallek14Michael von Bergwelt-Baildon15on behalf of the German CLL Study Group1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany2 Praxis für Hämatologie und Onkologie, Koblenz, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany6 Medizinische Klinik und Poliklinik I, University Hospital Dresden, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany8 University Clinic of Schleswig-Holstein, Kiel, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany9 Department of Medicine V, University Hospital Heidelberg, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germanyhttp://journals.lww.com/10.1097/HS9.0000000000000664 |
| spellingShingle | Natali Pflug Geothy Chakupurakal Anna-Maria Fink Sandra Robrecht Marco Herling Paula Cramer Udo Holtick Sebastian Theurich Johannes Schetelig Kirsten Fischer Matthias Ritgen Christof Scheid Barbara Eichhorst Peter Dreger Michael Hallek Michael von Bergwelt-Baildon on behalf of the German CLL Study Group Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies HemaSphere |
| title | Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_full | Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_fullStr | Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_full_unstemmed | Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_short | Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_sort | obinutuzumab in allogeneic transplantation for cll and richter s transformation in the age of targeted therapies |
| url | http://journals.lww.com/10.1097/HS9.0000000000000664 |
| work_keys_str_mv | AT natalipflug obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT geothychakupurakal obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT annamariafink obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT sandrarobrecht obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT marcoherling obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT paulacramer obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT udoholtick obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT sebastiantheurich obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT johannesschetelig obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT kirstenfischer obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT matthiasritgen obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT christofscheid obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT barbaraeichhorst obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT peterdreger obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT michaelhallek obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT michaelvonbergweltbaildon obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT onbehalfofthegermancllstudygroup obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies |